We are live on
!
Find out more
VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$160M
1-Year Est. Return
517.12%
This Fund
S&P 500
This Quarter
Est. Return
-5.48%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$97.2M
AUM Growth
-$18.7M
(-16%)
Cap. Flow
+$16.8M
Cap. Flow
% of AUM
17.25%
Top 10 Holdings %
Top 10 Hldgs %
76.66%
Holding
55
New
10
Increased
17
Reduced
2
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLRN
ACELYRIN
SLRN
|
+$8.01M |
| 2 |
SCPH
scPharmaceuticals
SCPH
|
+$2.99M |
| 3 |
Zevra Therapeutics
ZVRA
|
+$2.9M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$2.69M |
| 5 |
TELA Bio
TELA
|
+$1.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$7.18M |
| 2 |
Nurix Therapeutics
NRIX
|
+$1.84M |
| 3 |
Rezolute
RZLT
|
+$1.74M |
| 4 |
Kura Oncology
KURA
|
+$1.31M |
| 5 |
Collegium Pharmaceutical
COLL
|
+$822K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Heron Therapeutics
HRTX
$63.4M
| $15.4M | 15.81% |
6,986,744
| – | – |
|
|
SLRN
2
DELISTED
ACELYRIN
SLRN
| $8.32M | 8.56% |
+3,366,945
| New | +$8.01M |
|
|
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
| $8.19M | 8.42% |
185,520
| – | – |
|
4
Protara Therapeutics
TARA
$231M
| $7.1M | 7.31% |
1,667,800
+88,800
| +6% | +$397K |
|
|
5
Praxis Precision Medicines
PRAX
$10.2B
| $7.01M | 7.21% |
185,000
-115,000
| -38% | -$7.18M |
|
|
TRML
6
DELISTED
Tourmaline Bio
TRML
| $6.93M | 7.13% |
455,412
+31,617
| +7% | +$507K |
|
7
Jasper Therapeutics
JSPR
$26.6M
| $6.17M | 6.34% |
1,433,828
| – | – |
|
|
VRNA
8
DELISTED
Verona Pharma
VRNA
| $6.03M | 6.2% |
95,000
+45,000
| +90% | +$2.69M |
|
|
9
Zevra Therapeutics
ZVRA
$682M
| $4.98M | 5.12% |
665,000
+365,000
| +122% | +$2.9M |
|
10
Liquidia Corp
LQDA
$8.1B
| $4.42M | 4.55% |
300,000
| – | – |
|
11
InspireMD
NSPR
$37.5M
| $2.43M | 2.5% |
904,029
| – | – |
|
|
SCPH
12
DELISTED
scPharmaceuticals
SCPH
| $2.41M | 2.48% |
+917,668
| New | +$2.99M |
|
13
Mineralys Therapeutics
MLYS
$2.41B
| $2.39M | 2.46% |
+150,600
| New | +$1.73M |
|
14
Replimune Group
REPL
$1.15B
| $1.78M | 1.83% |
182,083
+716
| +0.4% | +$8.86K |
|
15
Edesa Biotech
EDSA
$50.5M
| $1.68M | 1.73% |
+687,500
| New | +$1.48M |
|
16
Instil Bio
TIL
$50.3M
| $1.2M | 1.23% |
+69,000
| New | +$1.43M |
|
|
17
Rezolute
RZLT
$451M
| $1.16M | 1.19% |
400,000
-400,000
| -50% | -$1.74M |
|
18
Eledon Pharmaceuticals
ELDN
$284M
| $1.1M | 1.13% |
323,973
| – | – |
|
19
Perspective Therapeutics
CATX
$342M
| $1.06M | 1.1% |
500,000
| – | – |
|
20
Geron
GERN
$949M
| $1.04M | 1.07% |
655,000
+606,000
| +1,237% | +$1.48M |
|
21
Immunome
IMNM
$2.91B
| $1.03M | 1.06% |
+153,500
| New | +$1.47M |
|
|
22
TELA Bio
TELA
$41.6M
| $912K | 0.94% |
+747,410
| New | +$1.84M |
|
23
Avalo Therapeutics
AVTX
$1.06B
| $897K | 0.92% |
111,972
+2,000
| +2% | +$15.2K |
|
24
Sutro Biopharma
STRO
$423M
| $670K | 0.69% |
103,000
+100,000
| +3,333% | +$1.57M |
|
|
UPB
25
Upstream Bio Inc
UPB
$405M
| $655K | 0.67% |
+107,000
| New | +$1.02M |
|
Similar funds
BFAG
SLG
SMF
LCA
SA
SGCM
RP
PCC
Velan Capital Investment Management's Q1 2025 Portfolio in Review
As of Q1 2025, Velan Capital Investment Management held 55 positions worth $97.2M, down 16% from $116M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Velan Capital Investment Management deployed $16.8M of net new capital in Q1 2025, opening 10 new positions and adding to 17 existing holdings. Its largest new stake was ACELYRIN: 3,366,945 shares worth $8.32M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $7.18M trimmed.
- Velan Capital Investment Management's largest Q1 2025 buy was ACELYRIN: 3,366,945 shares worth $8.32M.
- Velan Capital Investment Management added most to Zevra Therapeutics in Q1 2025, an estimated $2.9M increase.
- Velan Capital Investment Management's biggest Q1 2025 reduction was Praxis Precision Medicines, cutting an estimated $7.18M.
- Velan Capital Investment Management fully exited Nurix Therapeutics in Q1 2025, selling an estimated $1.84M.
- Velan Capital Investment Management's ten largest holdings make up 77% of its $97.2M portfolio in Q1 2025.
- Velan Capital Investment Management opened 10 new positions and closed 8 in Q1 2025.
- Velan Capital Investment Management's portfolio value fell 16% quarter-over-quarter to $97.2M.
Based on Velan Capital Investment Management's 13F filing for Q1 2025, filed 15 May 2025.